A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS‐CoV‐2. Issue 5 (17th January 2022)

• Record Type: Journal Article
• Authors: Malik, Prerna; Jain, Sonika; Jain, Pankaj; Kumawat, Jyoti; Dwivedi, Jaya; Kishore, Dharma
• Is Part Of: Archiv der Pharmazie. Volume 355:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-17
• Subjects: COVID‐19 pandemic -- Delta+ variant -- lopinavir -- remdesivir -- SARS‐CoV‐2 variant; Pharmaceutical chemistry -- Periodicals; Pharmacology -- Periodicals; 615.19
• DOI: 10.1002/ardp.202100382
• Languages: English
• ISSNs: 0365-6233

Abstract

Abstract: The outbreak of the coronavirus pandemic COVID‐19 created by its severe acute respiratory syndrome corona virus‐2 (SARS‐CoV‐2) variant, known for producing a very severe acute respiratory syndrome, has created an unprecedented situation by its continual assault around the world. The crisis caused by the SARS‐CoV‐2 variant has been a global challenge, calling to mitigate this unprecedented pandemic that has engulfed the whole world. Since the outbreak and spread of COVID‐19, many researchers globally have been grappling to find new clinically trialed active drugs with anti‐COVID‐19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activity and synthesis of some active molecules such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, lopinavir, camostat, chloroquine, baricitinib, molnupiravir, and so forth, which are under trial. Abstract : Since the beginning of the COVID‐19 pandemic, researchers worldwide have been searching for new clinically trialed active drugs with anti‐COVID‐19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activities and synthesis pathways of some active molecules under trial, such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, and others.